Metabolic Research//30mg
Retatrutide
$380.00
Investigational triple receptor agonist studied for GLP-1, GIP, and glucagon receptor pathway research.
Technical Dossier
Batch / Lot Number
—
Testing Status
—
Testing Laboratory
—
Test Date
—
Research Information
Retatrutide (LY3437943) is an investigational triple-receptor agonist with activity at the GIP, GLP-1, and glucagon receptors, studied in obesity and type 2 diabetes research. In a published phase 2 trial in 338 adults with obesity, once-weekly retatrutide produced dose-dependent weight loss over 48 weeks, with a 24.2% mean reduction at the 12-mg dose. Phase 3 trials are ongoing, and retatrutide is not approved for any indication. Supplied as a research-grade material for laboratory use only.
Explore the full Retatrutide Research ReviewAvailable Documentation
- Certificate of AnalysisPending / Not yet available
For Research Use Only
Products offered by Veridian Bioscience are intended for laboratory and research purposes only. They are not intended to diagnose, treat, cure, or prevent any disease and are not intended for human consumption.